Lu J, Lin L, Ye C, Tao Q, Cui M, Zheng S, Zhu D, Liu L, Xue Y

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 155-164
Archivo PDF: 197.82 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut 2017; 66: 541-53.

2. Arroyo V, Moreau R. Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis. J Hepatol 2017; 66: 451-53.

3. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P, Levesque E, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-47.

4. Karvellas CJ, Durand F, Nadim MK. Acute Kidney Injury in Cirrhosis. Crit Care Clin 2015; 31: 737-50.

5. Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol 2016; 65: 809-24.

6. Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, et al. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis 2017; 49: 202-6.

7. Aberg F, Lempinen M, Hollmen M, Nordin A, Makisalo H, Isoniemi H. Neutrophil gelatinase-associated lipocalin associated with irreversibility of pre-liver transplant kidney dysfunction. Clin Transplant 2014; 28: 869-76.

8. Ariza X, Sola E, Elia C, Barreto R, Moreira R, Morales-Ruiz M, Graupera I, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One 2015; 10: e0128145.

9. Ariza X, Graupera I, Coll M, Sola E, Barreto R, Garcia E, Moreira R, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol 2016; 65: 57-65.

10. Ahn HS, Kim YS, Kim SG, Kim HK, Min SK, Jeong SW, Jang JY, et al. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels. Hepatogastroenterology 2012; 59: 1168-73.

11. Finkenstedt A, Dorn L, Edlinger M, Prokop W, Risch L, Griesmacher A, Graziadei I, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int 2012; 32: 1211-6.

12. Allen AM, Kim WR, Larson JJ, Colby C, Therneau TM, Rule AD. Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. Transplantation 2015; 99: 1431-5.

13. Uguen T, Jezequel C, Ropert M, Houssel-Debry P, Latournerie M, Laine F, Deugnier Y, et al. Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation. Liver Int 2016; 36: 547-54.

14. Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, Moreau R, et al. Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis. Hepatology 2017; 66: 1232-41.

15. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, Chawla YK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8: 453-71.

16. Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Cytokeratin 18-based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients. Liver Int 2016; 36: 1464-72.

17. Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol 2018; 16: 162-77.

18. CM T, TO Y, J Y. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20: 6262-78.

19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’mico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

20. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-60.

21. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 0012; 367: 20-9.

22. Macdonald SPJ, Bosio E, Neil C, Arendts G, Burrows S, Smart L, Brown SGA, et al. Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis. Inflamm Res 2017; 66: 611-19.

23. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt- Ott KM, Viltard M, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17: 216-22.

24. Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, Borregaard N, et al. Liver is the major source of elevated serum lipocalin- 2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 2015; 61: 692-702.

25. Maiwall R, Sarin SK, Kumar S, Jain P, Kumar G, Bhadoria AS, Moreau R, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int 2017; 37: 1497-507.

26. Wang D, Feng JF, Wang AQ, Yang YW, Liu YS. Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients. Medicine (Baltimore) 2017; 96: e6949.

27. Culafic D, Stulic M, Obrenovic R, Miletic D, Mijac D, Stojkovic M, Jovanovic M, et al. Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. World J Gastroenterol 2014; 20: 6573-9.

28. Adachi M, Tanaka A, Aiso M, Takamori Y, Takikawa H. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis. Hepatol Res 2015; 45: 1299-306.

29. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology 2014; 59: 1532-42.

30. Wan Z, Wu Y, Yi J, You S, Liu H, Sun Z, Zhu B, et al. Combining serum cystatin C with total bilirubin improves shortterm mortality prediction in patients with HBV-related acute-on-chronic liver failure. PLoS One 2015; 10: e0116968.